Noradrenaline Sintetica (Norepinephrine)
Vasopressor infusion solution for emergency treatment of acute hypotension and septic shock
Quick facts about Noradrenaline Sintetica
Key Takeaways
- First-line vasopressor for septic shock: Noradrenaline Sintetica is recommended as the first-choice vasopressor by the Surviving Sepsis Campaign 2021 guidelines for hemodynamic support in septic shock, with a target mean arterial pressure of at least 65 mmHg
- Ready-to-administer 0.1 mg/ml formulation: Designed to reduce preparation time and eliminate manual-dilution errors in time-critical emergencies; the solution is used without further dilution in most protocols
- Central line administration only: Must be given through a central venous catheter; peripheral IV administration carries a significant risk of extravasation-induced tissue necrosis
- Continuous hemodynamic monitoring: Blood pressure, heart rate, ECG, urine output, and the infusion site must be monitored continuously throughout treatment in an intensive care environment
- Never discontinue abruptly: The infusion must always be tapered gradually to prevent rebound hypotension, which can be life-threatening in critically ill patients
What Is Noradrenaline Sintetica and What Is It Used For?
Noradrenaline Sintetica contains norepinephrine (noradrenaline), a potent endogenous catecholamine and vasopressor that constricts blood vessels to raise blood pressure. It is used in adults for the emergency treatment of acute hypotension, particularly septic shock, and is the first-line vasopressor recommended by international critical care guidelines.
Norepinephrine is a naturally occurring catecholamine synthesized in the postganglionic sympathetic nerve endings and the medulla of the adrenal glands. It serves as both a neurotransmitter in the central and peripheral nervous systems and a circulating hormone, playing a central role in the body's "fight-or-flight" response. Pharmaceutical-grade synthetic norepinephrine, such as Noradrenaline Sintetica, is chemically identical to the endogenous molecule and produces the same receptor-mediated effects when administered intravenously.
The primary therapeutic action of Noradrenaline Sintetica is potent stimulation of alpha-1 adrenergic receptors on vascular smooth muscle, producing rapid and powerful vasoconstriction. This raises systemic vascular resistance and both systolic and diastolic blood pressure. Norepinephrine also exhibits moderate beta-1 adrenergic activity, which increases cardiac contractility and to a lesser extent heart rate. Unlike epinephrine, it has negligible beta-2 activity, meaning it does not cause significant bronchodilation or vasodilation in skeletal muscle.
In clinical practice, Noradrenaline Sintetica is positioned as the first-line vasopressor recommended by the Surviving Sepsis Campaign (SSC) 2021 guidelines for the hemodynamic management of septic shock. It is preferred over dopamine because large randomized trials (including the SOAP II trial published in the New England Journal of Medicine) have demonstrated lower mortality and fewer adverse events — particularly fewer cardiac arrhythmias. The recommended initial mean arterial pressure (MAP) target during norepinephrine therapy is typically at least 65 mmHg, with individualized targets for patients with chronic hypertension, atherosclerotic disease, or specific organ dysfunction.
Beyond septic shock, Noradrenaline Sintetica is used in a broad range of critical care scenarios, including:
- Cardiogenic shock: Often in combination with inotropic agents such as dobutamine, to maintain coronary and end-organ perfusion
- Neurogenic shock: Following spinal cord injury or traumatic brain injury, where loss of sympathetic tone causes profound vasodilation
- Post-cardiac-surgery hypotension: To support blood pressure during and after cardiopulmonary bypass weaning
- Vasoplegic syndrome: A state of refractory vasodilation that may occur after cardiac surgery, anaphylaxis, or liver transplantation
- Post-anesthesia hypotension: Particularly in patients under general or neuraxial anesthesia when fluid therapy alone is inadequate
- Anaphylactic shock unresponsive to epinephrine: As a second-line agent in refractory cases
The Noradrenaline Sintetica 0.1 mg/ml (100 micrograms/ml) formulation is supplied as a ready-to-administer solution for infusion. This pre-formulated strength simplifies preparation and reduces the risk of calculation or dilution errors that can occur when reconstituting concentrated vials at the bedside. Ready-to-administer vasopressor formats have been endorsed by patient-safety organizations such as the Institute for Safe Medication Practices (ISMP) as a means of reducing medication errors in high-acuity settings. In most European critical care protocols the 0.1 mg/ml solution is infused without further dilution through a syringe pump or infusion pump.
Vasopressor therapy is part of a comprehensive hemodynamic strategy, not a substitute for it. Adequate fluid resuscitation (typically 30 ml/kg of balanced crystalloid over the first 3 hours of septic shock per SSC 2021 guidelines) should be initiated before or concurrently with norepinephrine. Using Noradrenaline Sintetica to mask persistent hypovolemia can worsen tissue perfusion, precipitate acute kidney injury, and increase the risk of peripheral ischemia. Source control, antimicrobial therapy, lactate monitoring, and ongoing reassessment of volume status are equally essential components of care.
What Should You Know Before Taking Noradrenaline Sintetica?
Noradrenaline Sintetica must never be administered through a peripheral intravenous line. It is contraindicated in patients with known hypersensitivity to norepinephrine or any excipients. Caution is essential in pre-existing cardiovascular disease, hyperthyroidism, peripheral vascular disease, and hypovolemic hypotension without adequate fluid replacement.
Contraindications
The following are absolute contraindications to the use of Noradrenaline Sintetica:
- Peripheral venous administration: The drug must not be given through a peripheral cannula or peripheral vein owing to the significant risk of severe local tissue necrosis from extravasation
- Known hypersensitivity: Documented allergy to norepinephrine or to any of the excipients (sodium chloride, disodium edetate, sodium metabisulfite where present, hydrochloric acid, sodium hydroxide, water for injections)
- Sulfite hypersensitivity: Formulations containing sodium metabisulfite (an antioxidant used to preserve norepinephrine) may provoke bronchospasm or anaphylactoid reactions in susceptible individuals, particularly those with asthma or a history of sulfite allergy
In a life-threatening hypotensive emergency, the treating clinician must weigh even absolute contraindications against the immediate risk of inadequate organ perfusion. For example, documented sulfite hypersensitivity may still permit cautious use when no alternative vasopressor is available, provided the patient is monitored for allergic reactions.
Warnings and Precautions
Additional vigilance, lower initial dosing, and intensified monitoring are required in the following patient groups and clinical scenarios:
- Severe left ventricular dysfunction: Noradrenaline Sintetica raises afterload, which can worsen cardiac output in patients with severe systolic heart failure. Advanced hemodynamic monitoring (e.g., echocardiography, pulse-contour cardiac-output analysis) is advisable, and combination therapy with an inotrope such as dobutamine may be required.
- Recent myocardial infarction or unstable ischemic heart disease: The increase in myocardial oxygen demand and coronary vasoconstriction can extend infarct size or provoke ischemia in patients with coronary artery disease.
- Cardiac arrhythmias: Beta-1 stimulation can precipitate or worsen ventricular or supraventricular arrhythmias. Continuous ECG monitoring is mandatory.
- Hyperthyroidism: Thyrotoxic patients have heightened cardiovascular sensitivity to catecholamines and a higher risk of severe hypertension and tachyarrhythmias.
- Diabetes mellitus: Norepinephrine elevates blood glucose through beta-2-mediated glycogenolysis and insulin suppression; diabetic patients may require intensified glucose monitoring and insulin titration.
- Hypovolemic hypotension: Low blood pressure due to bleeding or volume depletion should primarily be corrected with fluids and, where appropriate, blood products. Starting norepinephrine before volume resuscitation can exacerbate tissue ischemia, acute kidney injury, and lactic acidosis.
- Peripheral vascular disease: In patients with pre-existing atherosclerotic, diabetic, or vasospastic vascular disease (including Raynaud's phenomenon), alpha-1-mediated vasoconstriction may critically compromise blood flow to already ischemic extremities, occasionally leading to digital necrosis or gangrene.
- Cerebrovascular disease: Sudden blood pressure elevations may increase the risk of hemorrhagic stroke in patients with cerebral aneurysms, arteriovenous malformations, or recent intracranial hemorrhage.
- Mesenteric or peripheral thrombosis: High-dose norepinephrine can reduce splanchnic perfusion, potentially worsening intestinal ischemia.
Throughout treatment, the critical care team will continuously monitor blood pressure (preferably via an invasive arterial line), heart rate and rhythm, oxygen saturation, urine output, serum lactate, and the infusion site. Concomitant infusions through the same central lumen should be avoided where possible; if blood products or incompatible medications must be given, a dedicated line or separate lumen should be used.
If Noradrenaline Sintetica leaks from a central or peripheral vein into the surrounding subcutaneous tissue (extravasation), it can cause severe local vasoconstriction, ischemia, and tissue necrosis within hours. If extravasation is suspected, stop the infusion immediately, leave the cannula in place to aspirate residual drug, and infiltrate the affected area with phentolamine 5-10 mg diluted in 10-15 ml of 0.9% sodium chloride. Warm compresses and elevation of the limb are also recommended. A plastic-surgery consultation may be required if significant tissue injury has occurred. This is the primary reason why norepinephrine must be administered through a central venous catheter whenever feasible.
Pregnancy and Breastfeeding
Noradrenaline Sintetica should be used during pregnancy only when the potential benefit to the mother clearly outweighs the risks to the fetus. Norepinephrine crosses the placenta and can reduce uterine and placental blood flow, potentially causing fetal hypoxia and bradycardia. In the third trimester, its alpha-adrenergic activity may precipitate uterine contractions. Its use is generally restricted to life-threatening maternal hypotension where no safer alternative is available, and fetal monitoring is essential during administration in viable pregnancies.
There are no adequate data on the excretion of norepinephrine into human breast milk. Because the drug has a very short plasma half-life (approximately 2-3 minutes) and low oral bioavailability, significant infant exposure from breastfeeding is unlikely once the infusion is discontinued. Given that Noradrenaline Sintetica is used exclusively in acute critical care, breastfeeding decisions are typically secondary to stabilizing the mother's condition and are made in consultation with the treating clinicians.
Use in Children and Adolescents
Noradrenaline Sintetica is primarily indicated for adult patients. While norepinephrine is frequently used off-label in paediatric intensive care — including in the treatment of paediatric septic shock, as endorsed by the Surviving Sepsis Campaign paediatric guidelines — appropriate pediatric dosing protocols, dilutions, and concentrations are specialised and must be prescribed only by pediatric intensivists. The 0.1 mg/ml Sintetica formulation may be diluted or prescribed by weight-based protocols in neonatal and pediatric ICUs, but this should follow institutional guidelines specifically approved for pediatric use.
Use in Elderly Patients
No specific dose reduction is mandated for elderly patients based on age alone. However, older adults more frequently have cardiovascular comorbidities (coronary artery disease, heart failure, atherosclerosis) and reduced cardiovascular reserve, which justifies starting at the lower end of the dosing range and titrating cautiously. Age-related reductions in renal and hepatic function do not directly affect the pharmacokinetics of norepinephrine because the drug is inactivated rapidly in plasma by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO), but they may influence concurrent fluid management and the tolerability of cardiac stress imposed by increased afterload.
Sulfite Content
Some norepinephrine formulations, including certain Noradrenaline Sintetica preparations, contain sodium metabisulfite as an antioxidant to prevent oxidative degradation of the active ingredient. Sulfites can cause allergic-type reactions, including anaphylaxis and bronchospasm, particularly in patients with asthma. The prevalence of sulfite sensitivity in the general population is low, but clinicians should review the local Summary of Product Characteristics or package leaflet for the specific excipient list before use.
Sodium Content
Noradrenaline Sintetica 0.1 mg/ml contains sodium chloride as a tonicity agent. The total sodium content per vial varies by pack size, but in patients on strict sodium-restricted diets (e.g., severe heart failure, advanced chronic kidney disease, decompensated cirrhosis) the cumulative sodium load from prolonged high-volume vasopressor infusions should be included in the daily electrolyte balance.
How Does Noradrenaline Sintetica Interact with Other Drugs?
Noradrenaline Sintetica has clinically significant interactions with several drug classes, including halogenated volatile anesthetics, tricyclic antidepressants, SNRIs, MAO inhibitors, linezolid, methylene blue, cardiac glycosides, and ergot alkaloids. These interactions can result in life-threatening potentiation of blood pressure effects, cardiac arrhythmias, or hypertensive crisis.
Because norepinephrine acts directly on adrenergic receptors and is metabolized primarily by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT), drug interactions typically fall into two categories: pharmacodynamic (drugs that modify adrenergic signalling or myocardial excitability) and pharmacokinetic (drugs that inhibit its metabolism, thereby prolonging its action). Before starting Noradrenaline Sintetica, clinicians should perform a thorough medication reconciliation and review the patient's complete current and recent prescription list.
| Interacting Drug | Interaction Type | Clinical Effect | Severity |
|---|---|---|---|
| Halogenated volatile anesthetics (halothane, sevoflurane, desflurane, isoflurane) | Pharmacodynamic | Increased risk of ventricular arrhythmias. These agents sensitize the myocardium to catecholamine-induced electrical instability. | Major |
| Tricyclic antidepressants (imipramine, amitriptyline, nortriptyline) | Pharmacokinetic | Potentiated and prolonged pressor response by inhibition of norepinephrine reuptake at the synaptic cleft. | Major |
| Serotonin-norepinephrine reuptake inhibitors (venlafaxine, duloxetine) | Pharmacokinetic | Enhanced vasopressor effect via inhibition of norepinephrine reuptake, risking severe hypertension. | Major |
| MAO inhibitors (moclobemide, phenelzine, tranylcypromine, selegiline) | Pharmacokinetic | Dramatically enhanced and prolonged pressor response; may precipitate hypertensive crisis, stroke, or myocardial infarction. | Major |
| Linezolid (antibiotic) | Pharmacokinetic | Weak reversible MAO inhibition; can enhance norepinephrine's pressor effects, particularly in ICU patients on both drugs. | Moderate |
| Methylene blue | Pharmacokinetic | MAO inhibition can amplify norepinephrine levels; used together intentionally in refractory vasoplegic shock with careful titration. | Moderate |
| Cardiac glycosides (digoxin) | Pharmacodynamic | Additive risk of cardiac arrhythmias, particularly in patients with electrolyte disturbances (hypokalemia, hypomagnesemia). | Moderate |
| Ergot alkaloids (ergotamine, methylergometrine) | Pharmacodynamic | Enhanced vasoconstriction with risk of severe peripheral ischemia or hypertensive crisis. | Major |
| Beta-blockers (propranolol, metoprolol) | Pharmacodynamic | Unopposed alpha-1 activity may exaggerate vasoconstriction and hypertension; reflex bradycardia may also occur. | Moderate |
| Guanethidine, reserpine | Pharmacokinetic/Pharmacodynamic | Deplete presynaptic norepinephrine stores; upregulate postsynaptic adrenergic receptors, exaggerating response to exogenous norepinephrine. | Moderate |
Major Interactions
The most hazardous interactions arise with drugs that markedly amplify norepinephrine's cardiovascular effects. Halogenated volatile anesthetics remain a particular concern in the operating room. These agents sensitize the myocardium to the arrhythmogenic effects of catecholamines, so that usual doses of norepinephrine may precipitate ventricular tachycardia or fibrillation. In these patients, reduced initial doses and continuous ECG monitoring — along with correction of hypokalemia and hypomagnesemia — are essential.
Monoamine oxidase inhibitors represent one of the most dangerous pharmacokinetic interactions in modern pharmacology. MAO is one of the two principal enzymes responsible for inactivating norepinephrine. When MAO is inhibited — by classical irreversible agents (phenelzine, tranylcypromine), the reversible inhibitor moclobemide, or the selective MAO-B inhibitor selegiline — both endogenous and exogenous norepinephrine accumulate, producing exaggerated and sustained pressor effects. Severe hypertensive crises can lead to intracranial hemorrhage, aortic dissection, or myocardial infarction. In patients who have received MAO inhibitors within the preceding 14 days, norepinephrine should be started at a fraction of the usual dose (commonly 10-20% of the standard starting rate) with meticulous blood-pressure monitoring.
Tricyclic antidepressants and SNRIs (venlafaxine, duloxetine, atomoxetine) inhibit the presynaptic norepinephrine transporter, reducing synaptic clearance. The pressor response to exogenous norepinephrine is therefore both intensified and prolonged, necessitating significant dose reduction and prolonged hemodynamic observation.
Ergot alkaloids including ergotamine (used for migraine prophylaxis) and methylergometrine (used in obstetric hemorrhage) can cause direct vascular smooth-muscle vasoconstriction. Combined with norepinephrine, they can produce critical peripheral ischemia, hypertensive emergency, or coronary vasospasm.
Moderate Interactions
Linezolid, an oxazolidinone antibiotic used in the ICU for resistant Gram-positive infections, is a weak reversible MAO inhibitor. Although less severe than with dedicated MAOIs, the interaction can still enhance norepinephrine's pressor effects. Because both drugs are commonly used in critically ill patients, clinicians must remain vigilant for unexplained blood-pressure elevations during concurrent therapy.
Methylene blue, used as an antidote for methemoglobinemia and increasingly as a rescue therapy in refractory vasoplegic shock, also inhibits monoamine oxidase. In clinical practice these drugs are often used together intentionally, with careful dose titration and invasive blood-pressure monitoring.
Non-selective beta-blockers (e.g., propranolol) block the beta-adrenergic vasodilation induced by norepinephrine, leaving unopposed alpha-1-mediated vasoconstriction. This can produce exaggerated hypertension and reflex bradycardia. Selective beta-1 blockers (e.g., metoprolol, esmolol) pose less risk but still warrant caution.
Cardiac glycosides, principally digoxin, raise intracellular calcium in cardiomyocytes and increase the risk of catecholamine-induced arrhythmias. Correction of potassium and magnesium levels is essential when these drugs are used concurrently.
What Is the Correct Dosage of Noradrenaline Sintetica?
Noradrenaline Sintetica 0.1 mg/ml is administered as a continuous intravenous infusion through a central venous catheter only. The initial dose is typically 0.05-0.15 micrograms/kg/min, titrated within a maintenance range of 0.05-1.0 micrograms/kg/min (occasionally higher in refractory shock). All doses are expressed as norepinephrine base.
Dosing of Noradrenaline Sintetica is highly individualized and guided by the patient's hemodynamic response, underlying pathology, and concurrent therapies. The goal is to achieve and maintain a target mean arterial pressure (MAP) of at least 65 mmHg — or a patient-specific MAP target agreed with the treating team — using the lowest effective infusion rate. Continuous invasive arterial blood pressure monitoring is strongly recommended whenever norepinephrine is used for more than short, peri-procedural bolus support.
Unit convention: Throughout the European Summary of Product Characteristics and much of the international literature, norepinephrine doses are expressed as the free base. Some older North American references express doses as norepinephrine tartrate, which results in numerically higher values (1 mg of norepinephrine base corresponds to approximately 2 mg of norepinephrine tartrate). Clinicians should always verify which convention is being used on prescribing orders and infusion-pump labels.
Adults
Initial Dose
The typical starting dose is 0.05-0.15 micrograms/kg/min of norepinephrine base. Infusion is initiated at the lower end of this range and titrated upward based on the blood-pressure response and target MAP. For a 70 kg adult, this corresponds to a starting rate of approximately 0.2-0.6 ml/hour of the 0.1 mg/ml solution (approximately 3.5-10.5 micrograms/min). Preparation follows local ICU protocols; in most European hospitals the 0.1 mg/ml ready-to-administer solution is used without further dilution.
Maintenance Dose
The usual maintenance range is 0.05-1.0 micrograms/kg/min, although higher doses are occasionally required in refractory septic or vasoplegic shock. Once the patient reaches target MAP, the dose should be maintained at the lowest effective rate. Doses exceeding 1 microgram/kg/min should prompt a re-evaluation for unresolved hypovolemia, uncontrolled source of infection, adrenal insufficiency (where intravenous hydrocortisone may be appropriate per SSC 2021), or the need for adjunctive vasopressors such as vasopressin.
Dose Titration
Dose adjustments are typically made in increments of 0.02-0.1 micrograms/kg/min based on blood-pressure trends. After each change, a brief observation period of 5-10 minutes is usually allowed to assess the hemodynamic response before further adjustment. Rapid dose escalation should be reserved for persistent, life-threatening hypotension. Dose changes should always be accompanied by reassessment of volume status, cardiac output where available, and signs of end-organ perfusion (urine output, capillary refill, lactate).
Weaning
When the patient stabilizes and the underlying cause of shock is being addressed, Noradrenaline Sintetica should be weaned gradually, typically in decrements of 0.02-0.05 micrograms/kg/min every 15-30 minutes, while monitoring blood pressure closely. Abrupt discontinuation can precipitate rebound hypotension that is often more difficult to reverse than the original shock state, owing to persistent receptor desensitization.
| Phase | Dose Range | Target | Notes |
|---|---|---|---|
| Initial dose | 0.05-0.15 mcg/kg/min | MAP ≥ 65 mmHg | Start low, titrate based on response; use 0.1 mg/ml ready-to-use solution |
| Maintenance | 0.05-1.0 mcg/kg/min | MAP ≥ 65 mmHg; adequate end-organ perfusion | Use lowest effective dose; reassess doses above 0.5 mcg/kg/min |
| Refractory shock | > 1.0 mcg/kg/min (rescue) | Restoration of MAP | Consider adjunctive vasopressin, hydrocortisone, methylene blue |
| Titration increments | 0.02-0.1 mcg/kg/min per step | Gradual adjustment | Allow 5-10 min between adjustments; reassess volume status |
| Weaning | Decrements 0.02-0.05 mcg/kg/min | Hemodynamic stability off vasopressor | Never stop abruptly; typically every 15-30 min |
Children
Noradrenaline Sintetica is primarily approved for adult use. In paediatric critical care, norepinephrine is used according to specialised weight-based protocols, often starting at 0.05 micrograms/kg/min and titrating to a maximum of 2 micrograms/kg/min in refractory septic shock, as described in the paediatric Surviving Sepsis Campaign guidelines. Paediatric use should only be undertaken by paediatric intensivists familiar with appropriate dilution, administration, and monitoring protocols.
Elderly Patients
No formal age-based dose reduction is required. However, elderly patients frequently have diminished cardiovascular reserve, coronary artery disease, atherosclerosis, and greater sensitivity to vasoactive medications. Clinicians typically initiate therapy at the lower end of the dose range (0.05 micrograms/kg/min), titrate more cautiously, and monitor closely for evidence of myocardial ischemia (ECG changes, troponin elevation) or peripheral ischemia (cold extremities, delayed capillary refill). Chronic antihypertensive medications (especially beta-blockers and alpha-1 blockers such as tamsulosin) should be considered when interpreting the hemodynamic response.
Patients with Renal or Hepatic Impairment
Norepinephrine is rapidly inactivated in plasma and at adrenergic nerve terminals by MAO and COMT; it is not cleared meaningfully by the kidneys or liver. Therefore, no specific dose adjustment is required in patients with renal or hepatic impairment. However, underlying organ dysfunction may influence fluid management, electrolyte balance, and the patient's tolerance of increased cardiac workload.
Missed Dose
Because Noradrenaline Sintetica is administered only as a continuous hospital-based infusion, the concept of a "missed dose" does not apply in the conventional sense. However, unintended interruption of the infusion (e.g., pump malfunction, catheter occlusion, line disconnection) can cause abrupt hypotension. The nursing team must respond immediately by resuming the infusion at the previous rate and reassessing the patient. Institutions typically require dual-pump configurations or standby syringes for continuous vasopressors to allow rapid changeover without hemodynamic compromise.
Overdose
Overdose with norepinephrine manifests as an exaggeration of its pharmacological effects. Signs and symptoms include:
- Severe hypertension: Dangerously elevated systolic and diastolic pressures, potentially precipitating stroke, intracranial hemorrhage, hypertensive encephalopathy, or aortic dissection
- Reflex bradycardia: Baroreceptor-mediated slowing of the heart rate in response to severe hypertension
- Cutaneous vasoconstriction: Pallor, mottling, cold extremities, and progressive digital ischemia
- Cardiac arrhythmias: Ventricular ectopy, ventricular tachycardia, or ventricular fibrillation
- Myocardial ischemia: Chest pain, ST-segment changes, elevated troponins due to increased oxygen demand and coronary vasoconstriction
- Pulmonary edema: Resulting from increased afterload and reduced cardiac output
- Pressure necrosis: Skin ulceration at compressed or peripheral sites from prolonged severe vasoconstriction
Management of overdose involves immediate reduction or cessation of the infusion and supportive care. Because norepinephrine has a plasma half-life of only 2-3 minutes, pharmacological effects typically subside rapidly after discontinuation. If severe hypertension persists, short-acting intravenous vasodilators such as phentolamine (an alpha-adrenergic blocker), sodium nitroprusside, or nicardipine may be used. For refractory arrhythmias, standard Advanced Cardiac Life Support (ACLS) protocols apply, with correction of electrolyte imbalances and consideration of beta-blockade only after alpha-1 effects are controlled.
What Are the Side Effects of Noradrenaline Sintetica?
Like all medicines, Noradrenaline Sintetica can cause side effects, though not everyone experiences them. The most frequently observed effects reflect its pharmacological mechanism: hypertension, tachycardia or bradycardia, arrhythmias, cold and pale extremities, anxiety, headache, and tremor. Serious adverse events include severe arrhythmias, myocardial ischemia, peripheral gangrene, and tissue necrosis at the infusion site.
Adverse effects of norepinephrine are largely dose-dependent and represent exaggerations of its intended vasoconstrictive and cardiac-stimulant actions. Continuous hemodynamic monitoring in the ICU allows early detection and prompt dose adjustment, which minimizes the clinical impact of many side effects. The formal frequency of many adverse events is difficult to establish precisely because norepinephrine is typically used in critically ill patients whose underlying shock state produces overlapping clinical findings.
Peripheral Vascular Effects
- Cold and pale extremities and face
- Painful and cold hands and feet
- Mottled or cyanotic skin, delayed capillary refill
- Tissue hypoxia and reduced end-organ perfusion
- Peripheral digital ischemia (with prolonged high-dose use)
- Peripheral gangrene in severe or prolonged cases
Cardiovascular Effects
- Tachycardia (rapid heart rate)
- Bradycardia (reflex, typically secondary to hypertension)
- Cardiac arrhythmias (supraventricular and ventricular)
- Palpitations
- Increased myocardial contractility and oxygen demand
- Arterial hypertension (can be severe if overdosed)
- Acute heart failure in susceptible patients
- Myocardial ischemia or infarction (rare but serious)
Renal and Metabolic
- Oliguria or reduced urine output
- Acute kidney injury (with inadequate volume support)
- Elevated serum lactate
- Hyperglycemia
- Electrolyte disturbances (hypokalemia, hypomagnesemia)
Neurological and Psychological
- Anxiety and restlessness
- Headache
- Tremor
- Insomnia
- Confusion (particularly in elderly patients)
Ocular
- Acute angle-closure glaucoma (increased intraocular pressure)
- Mydriasis (pupil dilation)
- Photophobia
Respiratory
- Dyspnoea (shortness of breath)
- Respiratory difficulty
- Bronchospasm (particularly in sulfite-sensitive patients)
Gastrointestinal and Urinary
- Nausea and vomiting
- Urinary retention
- Reduced mesenteric blood flow
- Bowel ischemia (rare, with prolonged high-dose use)
Local Effects (Injection Site)
- Local irritation and phlebitis
- Pain along the vein
- Tissue necrosis from extravasation
- Skin ulceration and sloughing
Hypersensitivity Reactions
- Anaphylactoid reactions
- Bronchospasm in asthmatic patients
- Urticaria, rash, pruritus
- Angioedema (very rare)
Effects of Prolonged Administration
Continuous high-dose administration of Noradrenaline Sintetica to maintain blood pressure without correcting the underlying cause of shock or providing adequate fluid replacement can lead to a cascade of detrimental effects. These include:
- Severe peripheral and visceral vasoconstriction: Excessive narrowing of blood vessels in the extremities and internal organs, leading to ischemic complications
- Reduced renal blood flow: Potentially precipitating acute kidney injury and oliguria; renal-replacement therapy may become necessary
- Reduced splanchnic perfusion: Bowel ischemia, ileus, translocation of gut bacteria, and worsening systemic inflammation
- Tissue hypoxia: Widespread oxygen debt reflected in elevated serum lactate, metabolic acidosis, and worsened organ dysfunction scores
- Receptor desensitization: Down-regulation of adrenergic receptors over time, which can produce catecholamine-resistant shock and the need for adjunctive vasopressors (e.g., vasopressin, angiotensin II)
- Worse clinical outcomes: Higher cumulative norepinephrine doses are associated with higher mortality in observational studies of septic shock, which likely reflects both severity of illness and catecholamine-related harm
Hypersensitivity and Overdose-Related Effects
In patients with hypersensitivity to norepinephrine — or to excipients such as sodium metabisulfite — and in cases of overdose, additional symptoms may occur more frequently, including severe arterial hypertension, photophobia, retrosternal pain (chest discomfort behind the breastbone), pharyngeal pain (sore throat), pronounced pallor, intense sweating (diaphoresis), vomiting, and bronchospasm. These features demand immediate dose reduction and appropriate supportive care, including alpha-adrenergic blockade and bronchodilators where clinically indicated.
If you or someone you are caring for experiences side effects from Noradrenaline Sintetica, these should be reported to the treating medical team immediately. Healthcare professionals are also encouraged to report suspected adverse drug reactions to their national pharmacovigilance agency — for example, the FDA MedWatch program in the United States, the MHRA Yellow Card scheme in the United Kingdom, Swissmedic Vigilance in Switzerland, or the EMA EudraVigilance system across the European Union. Pharmacovigilance data are essential for identifying rare adverse events and refining clinical-practice guidance.
How Should You Store Noradrenaline Sintetica?
Store Noradrenaline Sintetica at or below 25°C (77°F), protected from light in the original outer carton. Do not freeze. Use immediately after first opening and discard any unused solution. Do not use if the solution appears darker than slightly yellow or pink, or if visible particles are present.
Proper storage of norepinephrine is critical for preserving both potency and safety. Norepinephrine is chemically unstable: it undergoes oxidative degradation in the presence of light, heat, alkaline pH, or certain metal ions. The degradation products — including adrenochromes and quinones — are pharmacologically inactive and may contribute to discoloration and local irritation. Adherence to the storage conditions specified by Sintetica S.A. is therefore essential.
- Temperature: Store at or below 25°C (77°F). Do not freeze. Avoid exposure to excessive heat or prolonged sunlight.
- Light protection: Keep vials or pre-filled syringes in the original outer carton to protect them from light. Norepinephrine is photosensitive and degrades more rapidly when exposed to UV and visible light.
- After opening: The product must be used immediately after first opening. Any unused solution should be discarded according to local institutional waste protocols. Do not store opened containers for later use.
- In-use stability: Once prepared in an infusion syringe or bag, in-use stability varies with the diluent, concentration, and container; follow your institution's pharmacy protocols and the manufacturer's Summary of Product Characteristics.
- Expiry date: Do not use after the expiry date (EXP) printed on the container and carton. The expiry date refers to the last day of the indicated month.
- Visual inspection: Before each use, inspect the solution. It should be clear and colourless to slightly yellow. Do not use if the solution has a deep yellow, brown, or pink discoloration, or if it contains particles or precipitates.
- Container integrity: Do not use vials that are damaged, cracked, or show signs of contamination around the stopper or seal.
- Keep out of reach of children: As with all medicines. Noradrenaline Sintetica is used exclusively in supervised hospital settings, but proper storage is still required in pharmacy and ward areas.
Unused medication and packaging should be disposed of in accordance with local institutional guidelines and environmental regulations. Norepinephrine and other pharmaceuticals should never be disposed of via household waste or wastewater systems, as these can contribute to environmental pharmaceutical pollution.
What Does Noradrenaline Sintetica Contain?
Each ml of Noradrenaline Sintetica 0.1 mg/ml solution for infusion contains 0.1 mg norepinephrine base (100 micrograms/ml), provided as norepinephrine tartrate. Excipients include sodium chloride, disodium edetate, potentially sodium metabisulfite as antioxidant, pH-adjusting agents (hydrochloric acid and/or sodium hydroxide), and water for injections.
Active Ingredient
The active substance is norepinephrine, chemically identical to the endogenous catecholamine, formulated as norepinephrine tartrate (also known as noradrenaline bitartrate or levarterenol bitartrate). Each millilitre of the Noradrenaline Sintetica 0.1 mg/ml solution contains 0.1 mg of norepinephrine base, equivalent to approximately 0.2 mg (200 micrograms) of norepinephrine tartrate. The molecular formula of norepinephrine is C8H11NO3 with a molecular weight of 169.18 g/mol.
Excipients (Inactive Ingredients)
- Sodium chloride: Used as a tonicity agent to render the solution isotonic with plasma and minimize local vascular irritation
- Disodium edetate (EDTA): A chelating agent that binds trace metal ions which would otherwise catalyze the oxidative degradation of norepinephrine, thereby extending shelf life
- Sodium metabisulfite (in some formulations): An antioxidant that prevents oxidation of the catechol group; may cause hypersensitivity in sulfite-sensitive patients
- Hydrochloric acid and/or sodium hydroxide: Used for pH adjustment during manufacture to maintain stability in the slightly acidic range (pH 3-4.5)
- Water for injections: Pharmaceutical-grade water serving as the vehicle
The specific excipient profile may vary between pack sizes and countries; always consult the package leaflet or Summary of Product Characteristics for the exact formulation approved in your region.
Physical Appearance
Noradrenaline Sintetica 0.1 mg/ml is a clear, colourless to slightly yellowish solution for infusion, presented in polypropylene pre-filled syringes or glass vials depending on the pack size and country of marketing. The low pH (typically 3-4.5) is maintained during manufacture to preserve stability.
The product is manufactured by Sintetica S.A., headquartered in Mendrisio, Switzerland. Sintetica is a specialty pharmaceutical company focused on sterile injectables used in hospital and critical care settings, including anesthetics, analgesics, and cardiovascular agents. The 0.1 mg/ml ready-to-administer concentration is designed to reduce preparation-related errors at the point of care, aligning with international patient-safety initiatives such as the ISMP High-Alert Medication guidance and WHO guidance on reducing harm from high-risk medications.
The solution is intended for single use only; any unused portion must be discarded after the infusion is completed. It is generally not mixed with other medicinal products in the same infusion line, because catecholamines are chemically incompatible with alkaline solutions (e.g., sodium bicarbonate) and certain other drugs that can precipitate or accelerate oxidative degradation.
Frequently Asked Questions
Noradrenaline Sintetica is used for the emergency treatment of acute hypotension (dangerously low blood pressure) in adults. It is the first-line vasopressor recommended by the Surviving Sepsis Campaign 2021 guidelines for septic shock and is also used in cardiogenic shock, neurogenic shock, post-cardiac surgery hypotension, vasoplegic syndromes, and other severe vasodilatory states. The medication constricts blood vessels by stimulating alpha-1 adrenergic receptors, thereby raising blood pressure and restoring organ perfusion. It is used exclusively in hospital settings, typically intensive care units and emergency departments, where continuous hemodynamic monitoring is available.
Ready-to-administer 0.1 mg/ml formulations such as Noradrenaline Sintetica reduce the risk of preparation and dilution errors that can occur when reconstituting concentrated vials at the bedside. They shorten the time to initiation of therapy in time-critical emergencies and allow standardized dosing protocols across hospital departments. Patient-safety organizations, including the Institute for Safe Medication Practices (ISMP), have endorsed ready-to-administer vasopressor formats as a strategy to reduce medication errors with high-alert drugs. The 0.1 mg/ml strength is a convenient concentration that balances pump-rate precision with manageable infusion volumes.
Noradrenaline Sintetica must be administered as a continuous intravenous infusion through a central venous catheter. It must never be given through a peripheral IV line, as extravasation (leakage into surrounding tissue) can cause severe tissue necrosis. The infusion rate is controlled precisely using a calibrated syringe pump or infusion pump. The 0.1 mg/ml formulation is supplied ready-to-administer without dilution in most European ICU protocols. Dose is typically titrated in micrograms per kilogram per minute to achieve a target mean arterial pressure of at least 65 mmHg.
Noradrenaline Sintetica (norepinephrine) and adrenaline (epinephrine) are both catecholamines but act differently on adrenergic receptors. Norepinephrine primarily stimulates alpha-1 receptors causing potent vasoconstriction with moderate beta-1 cardiac stimulation, making it the preferred vasopressor for raising blood pressure in septic shock. Epinephrine acts more equally on both alpha and beta receptors, producing stronger heart rate increases, bronchodilation, and cardiac contractility enhancement, making it the drug of choice for anaphylaxis, cardiac arrest, and severe asthma. At equipressor doses, norepinephrine causes less tachycardia and less myocardial oxygen demand than epinephrine, which is clinically relevant in patients with ischemic heart disease.
The most frequently reported side effects of Noradrenaline Sintetica include cardiovascular effects such as tachycardia, bradycardia, cardiac arrhythmias, hypertension, and palpitations. Peripheral vascular effects are also common, including cold and pale extremities, reduced blood flow to fingers and toes, and tissue hypoxia. Neurological effects such as anxiety, headache, and tremor may occur. Rare but serious complications include myocardial ischemia, peripheral gangrene, and tissue necrosis at the infusion site from extravasation. Most side effects are dose-dependent and can be managed with dose adjustment, optimization of volume status, and treatment of precipitating factors.
No. Noradrenaline Sintetica must never be stopped abruptly. Sudden discontinuation can cause acute, life-threatening rebound hypotension — often more severe than the original shock state, owing to receptor desensitization and residual underlying illness. The infusion must always be tapered gradually, typically in decrements of 0.02-0.05 micrograms/kg/min every 15-30 minutes, while monitoring blood pressure closely via an invasive arterial line. When the patient has recovered adequately, the dose is progressively reduced until hemodynamic stability is maintained without vasopressor support. The ICU team will individualize the weaning protocol based on the patient's response and underlying pathology.
Noradrenaline Sintetica must be given through a central venous catheter because of the serious risk of tissue damage if the drug leaks out of a peripheral vein (extravasation). Norepinephrine causes intense local vasoconstriction, and if it escapes into surrounding tissue it can cut off blood supply to the skin and underlying structures within hours, leading to ischemia, necrosis, and potentially requiring surgical debridement or amputation. Central venous catheters open into large-calibre vessels with high blood flow, which dilutes the drug rapidly and minimizes the risk of local injury. Short-term peripheral use may be considered only in urgent situations where central access is unavailable, and only for limited durations, with use of large proximal veins, dilute solutions, and immediate conversion to central access.
References
- Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Medicine. 2021;47(11):1181-1247. doi:10.1007/s00134-021-06506-y
- European Medicines Agency (EMA). Summary of Product Characteristics: Norepinephrine (noradrenaline). EMA product database. Accessed 2026.
- De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock (SOAP II). New England Journal of Medicine. 2010;362(9):779-789. doi:10.1056/NEJMoa0907118
- Overgaard CB, Dzavik V. Inotropes and vasopressors: review of physiology and clinical use in cardiovascular disease. Circulation. 2008;118(10):1047-1056. doi:10.1161/CIRCULATIONAHA.107.728840
- Annane D, Ouanes-Besbes L, de Backer D, et al. A global perspective on vasoactive agents in shock. Intensive Care Medicine. 2018;44(6):833-846. doi:10.1007/s00134-018-5242-5
- Weiss SL, Peters MJ, Alhazzani W, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatric Critical Care Medicine. 2020;21(2):e52-e106. doi:10.1097/PCC.0000000000002198
- World Health Organization (WHO). WHO Model List of Essential Medicines - 23rd List, 2023. Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Norepinephrine/Noradrenaline. NICE Evidence Services. Updated 2025.
- U.S. Food and Drug Administration (FDA). Norepinephrine Bitartrate Injection: Prescribing Information. FDA Drug Label Database. Accessed 2026.
- Institute for Safe Medication Practices (ISMP). ISMP List of High-Alert Medications in Acute Care Settings. ISMP; updated 2024.
- Reynolds PM, MacLaren R, Mueller SW, et al. Management of extravasation injuries: a focused evaluation of noncytotoxic medications. Pharmacotherapy. 2014;34(6):617-632. doi:10.1002/phar.1396
- Sintetica S.A. Noradrenaline Sintetica 0.1 mg/ml, solution for infusion - Summary of Product Characteristics. Mendrisio, Switzerland; updated 2025.
About Our Medical Editorial Team
This article was written and reviewed by iMedic's Medical Editorial Team, comprising board-certified physicians with expertise in critical care medicine, clinical pharmacology, and emergency medicine. Our content follows the GRADE evidence framework and adheres to the highest standards of medical accuracy, independence, and transparency.
All information is based on peer-reviewed research, international guidelines (SSC, EMA, FDA, WHO, BNF), and expert clinical consensus.
iMedic receives no commercial funding or pharmaceutical sponsorship. Our editorial independence ensures unbiased medical information.
Content is reviewed and updated regularly to reflect the latest medical evidence, guideline changes, and safety information.
Our content meets WCAG 2.2 AAA accessibility standards, ensuring medical information is available to everyone regardless of ability.